



SUBMITTING A LETTER OF MEDICAL NECESSITY

A letter of medical necessity can provide a detailed rationale for why your patient needs a specific treatment, based on her medical history

You may provide a letter of medical necessity if:

- Your patient's claim was denied and you are submitting an appeal letter
- You are requesting a formulary exception or tiering exception to get access for your patient

**HAVE A QUESTION?
CONTACT YOUR DEDICATED
ACCESS SPECIALIST**

**FOR SUPPORT OVER THE PHONE,
PLEASE CALL 1-800-ORILISSA (1-800-674-5477)**

Please see Important Safety Information on page 4.
Please [click here](#) for full Prescribing Information.

Orilissa® COMPLETE

WRITING A LETTER OF MEDICAL NECESSITY

BEFORE YOU GET STARTED, MAKE SURE YOU HAVE THE FOLLOWING FOR AN EFFICIENT SUBMISSION OF YOUR LETTER OF MEDICAL NECESSITY:

- Patient's insurance policy/ID number
- Case ID number if a decision has already been rendered
- Patient's full name, plan identification number, and date of birth
- A brief medical history, including diagnosis, allergies, existing comorbidities, and International Classification of Diseases (ICD) code(s)
- Clinical support for your recommendation
- Your office contact information

THE LETTER OF MEDICAL NECESSITY MAY BE DOWNLOADED ONLINE OR COME FROM THE PAYER



Download and complete the online template from Orilissa.com/hcp/letter-of-medical-necessity-sample-template

OR



Complete the patient's payer version of the letter of medical necessity if available

As you navigate through the template, please fill in information based on your clinical assessment for your specific patient. Be sure to also include any other pertinent information for your patient.

Digital version available at
Orilissa.com/hcp/letter-of-medical-necessity-sample-template
Please open file on PC only to ensure usability

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Providers are encouraged to contact third-party payers for specific information about their coverage policies. For more information, call an Access Specialist at 1-844-674-3676.

Please see Important Safety Information on page 4.

Please click [here](#) for full Prescribing Information.

Orilissa[®] COMPLETE

 Orilissa[®]
elagolix tablets 150 mg
200 mg

SAMPLE LETTER OF MEDICAL NECESSITY



Before completing the template, ask the payer whether a specific form is required to help establish medical necessity.

[Date]
[Payer Name]
[Payer Address]
Attn: [Appeals Department]
Re: [Patient Name]
[Policy ID/Group Number]
[Date of Service]

To whom it may concern:

My name is [name] and I am a [board-certified medical specialty] [NPI] writing on behalf of my patient, [patient name], to request coverage for [product, dosage, and frequency]. [Patient Name] has been under my care for [X] months for the treatment of [disease or symptoms].

I am writing this letter for medical necessity because, after working with [patient name], I believe that [product name] is the best treatment for this patient, and it's important that a formulary exception be made.

[Provide a brief medical history, including diagnosis, allergies, existing comorbidities, and International Classification of Diseases (ICD) code(s)].

[Discuss rationale for using <product name> vs other treatments. Insert your recommendation summary here, including your professional opinion of your patient's likely prognosis or disease progression without treatment.]

[List of pertinent medical records] are enclosed, which offer additional support for the formulary exception request for [product name]. Please consider coverage of [product name] for my patient.

Please contact me at [telephone number] to answer any pending questions. I would be pleased to speak to the medical necessity of [product name] for [patient's name]'s [diagnosis].

Thank you in advance for your attention to this request.

Sincerely,

[Physician name and signature]
[Physician's medical specialty]
[Physician's NPI]
[Physician's practice name]
[Phone #]
[Fax #]

Please see Important Safety Information on page 4.

Please click [here](#) for full Prescribing Information.

Orilissa[®] COMPLETE


Orilissa[®]
elagolix tablets 150 mg
200 mg

INDICATION AND IMPORTANT SAFETY INFORMATION FOR ORLISSA® (ELAGOLIX)

INDICATION¹

ORLISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION¹ CONTRAINDICATIONS

- ORLISSA is contraindicated in women who are pregnant (exposure to ORLISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment, in women taking organic anion transporting polypeptide (OATP) 1B1 inhibitors that are known or expected to significantly increase elagolix plasma concentrations, and in women with known hypersensitivity reaction to ORLISSA or any of its inactive components. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Bone Loss

- ORLISSA causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
- The impact of ORLISSA-associated decreases in BMD on long-term bone health and future fracture risk is unknown. ORLISSA is contraindicated in women with known osteoporosis. Consider assessment of BMD in patients with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss.
- Limit the duration of use to reduce the extent of bone loss.

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

- Women who take ORLISSA may experience a reduction in the amount, intensity, or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of pregnancy in a timely manner. Perform pregnancy testing if pregnancy is suspected, and discontinue ORLISSA if pregnancy is confirmed.

Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

- Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORLISSA in the endometriosis clinical trials.
- ORLISSA users had a higher incidence of depression and mood changes compared to placebo and ORLISSA users with a history of suicidality or depression had an increased incidence of depression. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to a mental health professional, as appropriate.

- Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORLISSA if such events occur.

Hepatic Transaminase Elevations

- In clinical trials, dose-dependent elevations of serum alanine aminotransferase (ALT) at least 3 times the upper limit of the reference range occurred with ORLISSA.
- Use the lowest effective dose and instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice.
- Promptly evaluate patients with elevations in liver tests to determine whether the benefits of continued therapy outweigh the risks.

Interactions with Hormonal Contraceptives

- Advise women to use effective non-hormonal contraceptives during treatment and for 28 days after discontinuing ORLISSA.
- Coadministration of ORLISSA 200 mg twice daily with an estrogen-containing contraceptive is not recommended because of the potential for increased estrogen-associated risks including thromboembolic disorders and vascular events. Coadministration of ORLISSA with an estrogen-containing contraceptive is expected to reduce the efficacy of ORLISSA.
- Coadministration with progestin-containing oral contraceptives may reduce the efficacy of the contraceptive. The effect of progestin-only contraceptives on the efficacy of ORLISSA is unknown. Coadministration of ORLISSA with progestin-containing intrauterine contraceptive systems has not been studied.

ADVERSE REACTIONS

- The most common adverse reactions (>5%) in clinical trials included hot flashes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions, and mood changes.

These are not all the possible side effects of ORLISSA. Safety and effectiveness of ORLISSA in pediatric patients have not been established.

Reference: 1. ORLISSA [package insert]. North Chicago, IL: AbbVie Inc; 2021.

Please click [here](#) for full Prescribing Information.

abbvie

©2021 AbbVie Inc. North Chicago, IL 60064 US-ORIL-210230 February 2021


Orilissa®
elagolix tablets 150 mg
200 mg